TEVA PHARMACEUTICALS USA, INC.

Lobbying for TEVA PHARMACEUTICALS USA INC

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 17, 2026

Expenses

$380,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

New Jersey

Official filing document

Government bodies contacted 9

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Use of Section viii statements in pharmaceutical labeling. Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and legislation to reform pharmacy benefit managers. Patent reform legislation. Proposals related to drug shortages. Reauthorization of the Pandemic and All Hazards Preparedness Act (PAHPA). Proposals related to biosimilar drugs. Proposals related to changes in prescription drug labeling. Proposals related to supply chain security and manufacturing.

Tariff (miscellaneous tariff bills)

A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada (S.J.Res.37). Tariff Transparency Act of 2025 (S.959) and Trump Tariff Transparency Act (H.R.6888).

Bills named in this filing 3

S.J. Res. 37
A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada.
S. 959
Tariff Transparency Act of 2025
H.R. 6888
Trump Tariff Transparency Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.